Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | HPN | P05981 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797138 | 1.00 | ADAMTS7 (0.38) | ADAMTS7ADAMTS5PLAUHPNMMP13 | |
| SCHEMBL1798953 | 0.88 | ADAMTS7 (0.45) | ADAMTS7ADAMTS5PLAUHPNMMP13 | |
| SCHEMBL1798952 | 0.88 | ADAMTS7 (0.45) | ADAMTS7ADAMTS5PLAUHPNMMP13 | |
| SCHEMBL1802731 | 0.86 | ADAMTS7 (0.44) | ADAMTS7ADAMTS5PLAUMMP13MMP1 | |
| SCHEMBL1802730 | 0.86 | ADAMTS7 (0.44) | ADAMTS7ADAMTS5PLAUMMP13MMP1 | |
| SCHEMBL1798436 | 0.78 | ADAMTS7 (0.46) | ADAMTS7ADAMTS5MMP13 | |
| SCHEMBL1798439 | 0.78 | ADAMTS7 (0.46) | ADAMTS7ADAMTS5MMP13 | |
| SCHEMBL1801386 | 0.77 | ADAMTS7 (0.50) | ADAMTS7ADAMTS5PLAUHPNMMP13 | |
| SCHEMBL1801383 | 0.77 | ADAMTS7 (0.50) | ADAMTS7ADAMTS5PLAUHPNMMP13 | |
| SCHEMBL1802212 | 0.76 | ADAMTS7 (0.45) | ADAMTS7ADAMTS5MMP13MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | claimed |
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1461313-B1 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | ADAMTS7 53/4885ADAMTS5 36/4885PLAU 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.